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yperhomocysteinemia (Hcy) is an independent risk factor for cardiovascular diseases (CVD) and 
associated with primary causes of mortality and morbidity throughout the world. Association between Hcy 
and CVD has been a question for biologists over the last five decades. The circulating levels of Hcy can 
be increased by defects in enzymes involved in the metabolism of several B and therefore for homocysteine.  
Although researchers have yielded conflicting findings on the link between homocysteine and CVD risk, but there 
is convincing evidence on link between B vitamin deficiencies and increased CVD risk. This review identifies the 
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Introduction  
The burden of non-communicable chronic diseases, 
including the CVDs, is rapidly rising around the globe, 
affecting all parts of world’s population [1]. 
Contrarily to the previous classification of chronic disea
ses as "diseases of affluence" they are now arising at a 
much faster rate in poorer countries than in developed 
areas of the world [2]. According to cardiovascular 
diseases account for around 30% of global deaths, and 
this figure is expected to increase further by 2030 [3]. 
While deaths   caused due to CVD decreased by 31% 
between 2000 and 2010 [4], it is still projected to continue 
to be the world’s leading cause of death. Given 
substantial research in the field of its prevention and 
treatment, CVD infests the developed and developing 
regions alike. It is accounted for one in every three 
deaths [1], while 80% of total deaths caused by CVD 
have been reported to occur in resource limited countries 
[3]. Asian and African regions of the world are showing 
highest mortality and prevalence of cardiovascular 
diseases in the world. People with old age are the main 
victims of heart disease. Cardiovascular disease is one 
out of five major causes of “years lived with disability” 
(YLD) in poor countries [5]. CVD causing premature 
deaths thus ask for more health care budgets and 
reducing the GDP by 6.77% together with diabetes [6]. 
Almost all the parts of World’s population are facing a 
rise in non-communicable chronic diseases. 
Cardiovascular diseases are one of them which are 
focusing the underdeveloped population [7]. Research 
for prevention and treatment is still unable to control 
cardiovascular diseases in developed and developing 
countries [8]. This review summarizes the research 
conducted on Hcy and provides a framework for factors 
associated with Hcy and CVD.        
Methods 
Literature search strategy and selection criteria 
References included in this review article were searched 
by using NCBI (PUBMED) and Google scholar, by the 
use of terms Hcy CVD, Methionine, Homocysteine. 
Articles resulting from these searches were reviewed 
and relevant references were cited in this review article. 
This included articles published in English. Case reports 
published online were also included in this study. We 
selected 24 peer reviewed research articles and 35 
review articles for this study. 
Discussion 
Risk factors for development of CVD 
The detection of risk factors plays a key role in primary 
prevention of chronic diseases. Like other non-
communicable diseases, several factors which increase 
the possibility of developing CVD have also been 
reported, including hypertension, smoking, diabetes, 
high serum cholesterol and obesity [9].  
Overview of Homocysteine metabolism 
Homocysteine (HCY), a sulfur metabolite-containing 
essential amino acid, methionine, is formed regularly 
during methionine metabolism and its low concentrations 
(5-15µmol/L) are normally present in the plasma. HCY 
metabolism requires two separate pathways (trans- 
sulfuration and remethylation), dependent upon B 
vitamins [10]. The pathway of transsulfuration is 
triggered at times when methionine is present in excess 
amounts. During this cycle, HCY is converted to 
crystathione and subsequently converted to cysteine. 
Vitamin B6 (pyridoxine) acts as a cofactor, HCY is largely 
remethylated during the periods of low methionine to be 
converted back to methionine [11]. During metabolism of 
sulfur containing amino acid, homocysteine is produced 
as a metabolite whose normal plasma concentration is 
5-15 µmol/L [12]. In the presence of in excess amount of 
methionine, transsulfurationpathway is activated to 
convert homocysteine to crystathione leading to the 
formation of cysteine. But in the presence of low levels 
of methionine, re-methylation of homocysteine starts to 
synthesize methionine [13]. Methyl tetrahydrofolate 
(from Vitamin B9) and Vitamin B12 act as cofactors in this 
process [14]. Both of these pathways require the 
mediation of S-adenosylmethionine (SAM) and S-
adenosylhomocysteine (SAH). High levels of HCY are 
linked to reduced methylation potential, whereas this 
potential is increased by the presence of Vitamins B9 and 
B12 [15]. High levels of HCY have been considered a risk 
factor for cardiovascular disease for nearly half a 
century, the association between genetic disability to 
breakdown HCY and premature atherosclerotic disease 
was reported [16]. The hypothesis discussed above has 
been researched several times and found conflicting and 
inconsistent results. Recent research community has 
observed the linkage between CVD and abnormally high 
levels of HCY which suggests HCY as a new risk factor 
for coronary artery disease (CAD) [17]. A cohort study 
showed the independent association of HCY level with 
all-cause plus cardiovascular mortality [18]. A study 
found increased HCY in patients with ischemic heart 
disease (IHD) as compared to those of controls. It was 
also demonstrated that increased HCY is a factor for 
cardiovascular disease as well as atherosclerosis in IHD 
patients [19]. In 2005, Chua with his team studied the 
association of HCY and coronary lesion risk in Chinese 
population with acute myocardial infarction. They 
suggested the higher HCYconcentration is a major risk 
factor for coronary atherosclerosis [20]. Vitamin B 
supplementation to control the increased levels of HCY 
has no significant improvement in carotid intima medial 
thickness (CIMT) and flow mediated dilation (FMD) but 
pooled effect showed little improvement in FMD and 
CIMT with HCY reduction [21]. A study was reported 
which showed double-blind placebo controlled for 
treating increased HCY by folic acid and it was found 
considerable improvement in study subjects. On the 
other hand no significant improvement was observed in 
case of atherosclerosis or carotid distensibility [22]. 
Another meta-analysis of 8 randomized, placebo-
controlled study, folic acid showed decrease in HCY 
levels by 25% over the period of 5 years on average. No 
major impact was observed on other cardiovascular 
events including arterial revascularization [23]. 
It was found that vitamin B supplementation plays no 
significant role for the prevention of CVD [24]. Folic acid 
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is effective for CVD prevention in patients who are also 
affected by kidney disease [25]. In a meta-analysis 
studies, it was found high HCY levels as an independent 
predictor of mortalities including CVD mortalities [26]. 
The arterial inflexibility has been found to cause 
occurrence of first CVD in community based 
Framingham Heart Study [27]. High HCY levels have 
been observed in IHD patients in Homocystein Slovakia 
cross-sectional population showing the association 
between increased homocysteine and CVD [28]. Another 
study also showed the similar relationship between CVD 
and hyper-homocysteinemia [29]. Meta analyses of 17 
studies showed the increased levels of HCY(5umol/L) as 
a risk factor for CAD and increase in cholesterol level 
[30]. Another meta-analysis study did not agree with[31]. 
In this meta-analysis, no relationship was found between 
higher HCY and coronary artery disease. Another meta-
analysis study showed decrease in homocysteine levels 
by 3umol/L was shown to decrease the risk of IHD by 
16% [32]. It will also decrease the risk of deep vein 
thrombosis and stroke by 25% and 24% respectively. 
Including 72 case control studies and 20 prospective 
studies, it was evident that decrease in HCY levels 
decreases the cardiovascular disease risk. In HCY 
collaboration study 2002, increase in HCY levels was 
suggested to be an independent and modest predictor of 
IHD and stroke. Other meta-analysis of 24 retrospective 
and 3 prospective studies, showed some association 
between increased HCY and venous thrombosis [33]. 
Despite of a large number of studies on causes, 
treatment and mechanism of increased levels of HCY, 
confusions and contradictions exist about the 
association of HCY and CVD which needs more studies 
[34]. 
 
Hyperhomocysteinemia and its determinants 
Homocysteinuria is characterized by huge elevations in 
HCY levels (as high as 50 times their normal values), 
premature thrombosis and cardiovascular illnesses.  It 
results from rare inborn errors in HCY metabolism, in 
which defects in certain enzymes crucial for HCY 
metabolism lead to the accumulation of HCY in blood 
and ultimately passage in urine occur [35].  Slight 
increments (15-25µmol/L) in HCY concentration may, 
however, be due to dietary factors associated with its 
metabolism [36]. Many genetic and environmental 
factors are now known to determine the HCY levels 
including lifestyles, behaviors, old age, maleness 
smoking, caffeine, menopause, chronic alcohol intake, 
deficiency of vitamins and impairment of renal function. 
It was indicated that independently of other lifestyle 
factors, age, and intake of folate and B vitamin 
supplements, reducing smoking and coffee intake could 
result in a 0.1- to 1.7-μmol/liter change in plasma total 
HCY level. This study also suggested that avoiding 
smoking, caffeine and folate and vitamin B 
supplementation shows decrease in plasma 
homocysteine levels [37]. 
The association between HCY concentrations, 
demographic and lifestyle factors as well as with B 
vitamin status was also investigated. Plasma tHCY was 
found to be higher in non-users of vitamin supplements. 
A survey was conducted to observe the association of 
HCY with lifestyle and vitamin B supplementation which 
showed the supplement users on much safer side [38].  
In fact, increased concentrations of HCY are genetically 
determined. Some genotypes are known to cause rare 
types of conditions linked with premature 
atherothrombosis. Gene mutations are responsible for 
the loss of some enzymes including 
Methylenetetrahydrofolatereductase (MTHFR) and 
Crystathione b- synthase (CBS) linked to plasma HCY 
levels [29]. Certain rare genotypes have shown the 
association with premature atherothrombosis. The gene 
mutations in Methylenetetrahydrofolatereductase 
(MTHFR) and Crystathioneβ-synthase (CBS) have been 
shown to be associated with hyper-homocysteinimia 
[29]. 
 
Possible mechanisms involved in linking HCY with 
CVD 
In spite of the partial recognition of HCY as a risk factor 
for CVD, the biological mechanisms involved in this 
relationship have not been completely identified. 
However, several mechanisms have been proposed to 
explain the relationship of hyperhomocysteinemia 
(HHCY) with the development of vascular disease. 
These potential mechanisms include endothelial 
dysfunction, production of reactive oxygen species 
(ROS) with consequent LDL oxidation, increased 
monocyte adhesion, activation of coagulation factors and 
inflammatory pathway and hypofibrinolysis caused by 
HHCY [39]. 
Atherosclerosis, being an inflammatory process, has 
been suggested to exhibit rapid progression due to the 
role of HCY in chronic inflammation [40]. HCY has been 
known to enhance the development of several pro 
inflammatory cytokines, which can contribute to 
atherogenesis by influencing vascular inflammation [41]. 
HCY has also been studied to impair normal cellular 
function, including vascular endothelial cells. This role of 
HCY has been supported in a study, in which it was 
found that increments in HCY levels can induce vascular 
endothelial dysfunction.  HHCY hasbeen recognized to 
impair endothelial vasodilation-an early step in 
atherosclerotic lesion development. This role of HCY in 
causing cellular dysfunction has been suggested (not 
validated) to be due to the involvement of reactive 
oxygen species (ROS) produced by auto oxidation of 
HCY. HCY has also been studied to lower nitric oxide 
bioavailability (the vasodilator) and decreasing the 
expression of antioxidant enzymes. Vascular injury due 
to the ability of HCY to cause endoplasmic stress is 
another mechanism of vascular injury [41]. Another 
different mechanism for linking CVD and HCY was 
observed. Reduced mRNA for atheroprotective 
lipoprotein Apo A-1 and thus reduced concentration of 
Apo A-1 was identified in MTHFR deficient mice. The 
findings of their study showed that HHCY may contribute 
to CVD by decreased Apo A-1 expression, which is the 
main protein component of HDL [42]. As previously 
mentioned, HDL is known for its roles in CVD protection 
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and its negative relation with HCY indicates CVD risk 
development. This role of HCY in reducing HDL 
production was also supported in which a strong 
negative correlation was established between plasma 
HCY and HDL levels[43]. HHCY secondary to genetic 
causes as well as dietary HHCY has been found to cause 
significant increase in HCY-thiolactone, which is an 
atherogenic metabolite. These studies support that 
HHCY is associated with several mechanisms which 
promote CVD, providing a basis for establishing a direct 
role of HCY in raising cardiovascular disease risk [44].   
Role of dietary factors  
As already mentioned, HCY being an intermediate 
produced during methionine metabolism, is normally 
present in the plasma. But the concentrations are 
maintained by the mechanisms responsible for its 
conversion into either cysteine or into methionine itself. 
The role of B vitamins as cofactors in HCY metabolism, 
predispose a vitamin deficient person to HHCY and thus 
to CVD development. Administration of methionine and 
provision of vitamin (cobalamin, choline, folate and / 
pyridoxine) deficient diets have been used as model for 
inducing experimental HHCY, in addition to genetic 
alterations of enzymes involved in HCY metabolism. The 
use of these approaches indicates the important role of 
certain dietary factors in influencing plasma HCY levels 
[45].  A study reviewed by Elmadfa  concluded that 
vegetarians, especially vegans, are at risk of developing 
HHCY due to low dietary intake of Vitamin B12 which is 
found predominantly in animal foods [46]. The authors 
recommended the use of well-planned vegetarian diets 
to avoid such complications. Folate is available in variety 
of plant and animal foods including liver, mushrooms and 
green leafy vegetables (especially spinach, broccoli). 
The food sources of vitamin B6 include meats, whole 
grains, vegetables and nuts, with greater bioavailability 
of pyridoxine derived from animal foods. Vitamin B12 is 
found in foods bound to protein and thus, high protein 
foods including egg, fish, meat, organ meats, milk, and 
cheese are its richest sources [47]. As folate and vitamin 
B12 do not share the same food sources, therefore a 
careful planning is required to fulfill the requirements of 
these vitamins. A well-balanced diet including all food 
groups can be of benefit [48]. High dietary protein intakes 
have also been found to increase circulating HCY levels, 
as HCY is an amino acid metabolite. In a dietary 
controlled study, a high protein diet (containing 21% 
energy from proteins or 4-4.5g methionine per day) was 
demonstrated to increase total HCY levels throughout 
the day. Fasting HCY levels were not affected by one 
week high protein diet, indicating the effects of overnight 
fast on normalizing HCY levels [49]. 
A large body of research support the role of folate in 
decreasing HCY levels and folic acid supplementation 
has now been suggested as a safe preventive measure 
in high risk individuals. Dietary deficiency of Vitamin B6, 
B9 and absorptive insufficiency of vitamin B12 are 
important factors responsible for HHCY. Therefore, 
dietary improvement by providing the food sources of B 
vitamins in abundance may prevent vascular disease by 
lowering serum HCY [40]. tHCY levels can be reduced 
by increasing the intake of fruits and vegetables by 
enhancing dietary folate intake. Patients with 
hypercystenemia and cardiovascular disease have 
shown improvement with a daily dose of folic acid at a 
concentration of 0.65-10mg [50]. However, supplemental 
folate can mask the neurological symptoms of B12 
deficiency if it occurs at the same time. Therefore, 
simultaneous supplementation of both vitamins is 
recommended. Administration of recommended dose 
(1mg/day) of vitamin B12 can cause 10-15% reduction in 
HCY levels. The effect of B12 supplementation has been 
found to increase nitric oxide concentrations and an 
improvement in endothelial function. Pyridoxine (vitamin 
B6) in a dosage of 10-250 mg/day along with 
folatetherapy, has a greater effect on HCY lowering than 
folate administration alone. However, chronic 
administration of B6 may result in peripheral neuropathy 
[51]. The relationship of folate and HCY concentration in 
Mediterranean IHD patients was investigated, IHD 
patients had lower folate intakes and serum folate levels 
as compared to the controls. Dietary folate intake was 
found to have a strong influence on fasting HCY levels 
[49]. Combination of vitamins rather than either one 
alone has been found to have much pronounced effect 
on HCY lowering. A randomized placebo controlled 
intervention showed a significant improvement in HCY 
levels with B vitamin supplementation [21]. A meta-
analysis was conducted to assess the Meta-analysis for 
investigating the effects of different doses of folate 
supplementation on HCY levels as well as the effects of 
combination therapy of B12 and B6 with folate. The 
authors, after analyzing 25 randomized controlled trials, 
concluded that daily dose of more than0.8 mg/ day of 
folic acid are required to achieve maximum HCY 
reduction. Recommended a dose of folate (0.8mg/day) 
for considerable reduction in high homocysteine levels 
[52].  Vitamin B12 was found to be associated with 
additional 7% reduction in HCY levels but B6 
supplementation along with folate did not appear to have 
a significant effect [53]. Therefore, combined 
administration of vitamins B9 and B12 were found to 
have greater effect than either one alone [54]. Similar 
results have previously been found in comparatively 
smaller meta-analysis [55]. A much lower dose of folate 
supplementation (0.5- 5mg/day) along with 0.5 mg of B 
12 was found to reduce HCY levels by a quarter to a 
third. This difference might have been due to the 
inclusion of older data in that meta-analysis. Vitamin B6 
was not found to have a significant role in HCY lowering, 
as was found in 2005 meta-analysis [56]. Although the 
role of B vitamins in HCY lowering has been established, 
studies on the effects of this lowering on subsequent 
cardiovascular events have yielded conflicting results. In 
a randomized placebo controlled trial, daily folic acid 
dose of 800μg for three years was found to decrease 
plasma t HCY levels by 26% in 819 adults with HHCY. In 
spite of the improvement in HCY concentration, folate 
supplementation was unable to slow down the 
development of atherosclerotic lesion or progression of 
arterial stiffening [22]. 
Heart outcomes Prevention Evaluation 2 determined 
the prolonged effects of Vitamin B9, B12 and B6 
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administration on vascular events in high risk population. 
the results of this large, prospective, randomized clinical 
trial report that although HCY levels were significantly 
reduced by daily supplementation of folic acid, 
pyridoxine and cobalamin over a period of five years but 
did not reduce the cardiovascular disease incidence [57]. 
A meta-analysis on the use of Vitamin B supplement was 
conducted that showed decrease in HCY and 
improvement in endothelial function in short term trails 
only [21]. Therefore, despite the well-known role of 
dietary factors in reducing HCY levels, their effects on 
lowering the CVD risk are still not validated. The studies 
have produced inconsistent data on the influence of HCY 
lowering achieved by vitamin supplementation on 
reducing cardiovascular disease incidence. Therefore, 
this subject requires further investigation [58].  
Risk factor control as primary prevention of CVD 
A large body of data strongly supports investments in 
prevention as the most sustainable solution for CVD 
endemic. Clear evidence supports the fact that primary 
prevention and individual health care interventions play 
an important role in reducing the disease burden. 
Reducing cardiovascular risk factors has been 
responsible for more than 50% decline in CVD mortality 
[59]. Several modifiable risk factors can be targeted for 
CVD risk prevention in high risk as well as in general 
population. Behavioral risk factors, including smoking, 
physical inactivity, alcohol abuse, and unhealthy diet, 
have been linked to vascular disease development and 
progression. Identification of these easily modifiable 
factors can lead to prevention of majority of fatal 
cardiovascular events [60]. Promotion of knowledge 
about the CVD risk factors as well as their control 
therefore, remains a strategy for rapid decline in the CVD 
prevalence. High plasma HCY levels have been 
identified to be linked to CVD and their causal 
relationship has been identified. Presence of some CVD 
risk factors can result in HHCY. Reductions in smoking 
and taking a healthy diet can be used as approaches for 
lowering HCY concentrations. In addition, certain dietary 
modifications can also result in improvement in HCY 
levels. Dietary intake or supplementation of vitamins B9, 
B6 and B12 can be of benefit [61].  
Conclusion 
In spite of a variety of knowledge on the subject, the 
association between HCY and CVD remains conflicting. 
However, the current evidence suggests a possible role 
of high levels of HCY in causing CVD and opens new 
avenues for researches in the field of nutrition, public 
health and medicine.  
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